Viviana Maestrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3940143/publications.pdf

Version: 2024-02-01

218677 161849 4,520 58 26 54 citations h-index g-index papers 60 60 60 4678 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prognostic role of pre- and postinterventional myocardial injury in patients undergoing transcatheter aortic valve implantation. Minerva Cardiology and Angiology, 2023, 71, .	0.7	5
2	Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Failure Reviews, 2023, 28, 709-721.	3.9	14
3	Hypertrophic cardiomyopathy: insights from extracellular volume mapping. European Journal of Preventive Cardiology, 2022, 28, e39-e41.	1.8	6
4	ECG evaluation in 11 949 Italian teenagers: results of screening in secondary school. Journal of Cardiovascular Medicine, 2022, 23, 98-105.	1.5	4
5	3D Echo Characterization of Proportionate and Disproportionate Functional Mitral Regurgitation before and after Percutaneous Mitral Valve Repair. Journal of Clinical Medicine, 2022, 11, 645.	2.4	2
6	Complex connections: A young man presenting with shortness of breath, hypoxemia, right lumbar pain and left limb swelling. Echocardiography, 2022, , .	0.9	1
7	Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 16.	3.3	30
8	Impact of intraventricular haemodynamic forces misalignment on left ventricular remodelling after myocardial infarction. ESC Heart Failure, 2022, 9, 496-505.	3.1	12
9	Systematic Cardiovascular Screening in Olympic Athletes before and after SARS-CoV-2 Infection. Journal of Clinical Medicine, 2022, 11, 3499.	2.4	6
10	Susceptibility to ischaemic heart disease: Focusing on genetic variants for ATP-sensitive potassium channel beyond traditional risk factors. European Journal of Preventive Cardiology, 2021, 28, 1495-1500.	1.8	22
11	T2-mapping increase is the prevalent imaging biomarker of myocardial involvement in active COVID-19: a Cardiovascular Magnetic Resonance study. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 68.	3.3	27
12	The role of cardiovascular magnetic resonance in the screening before the return-to-play of elite athletes after COVID-19: utility o futility?. Journal of Sports Medicine and Physical Fitness, 2021, 61, 1137-1143.	0.7	4
13	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 7650.	4.1	17
14	Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. International Journal of Cardiology, 2021, 339, 235-242.	1.7	28
15	Potential Role of eNOS Genetic Variants in Ischemic Heart Disease Susceptibility and Clinical Presentation. Journal of Cardiovascular Development and Disease, 2021, 8, 116.	1.6	18
16	Left ventricular wall stress is associated with myocardial functional recovery in patients with severe aortic stenosis and systolic dysfunction undergoing transcatheter aortic valve replacement. Journal of Cardiovascular Medicine, 2021, 22, 66-68.	1.5	3
17	590 ACE-I and ARBS do not influence the chest CT presentation and 1-year survival of COVID-19 patients: Italian multicentre registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
18	$511\hat{a}$ \in f Cardio-vascular remodelling during sacubitril/valsartan therapy in patients with heart failure and reduced ejection fraction. European Heart Journal Supplements, 2021, 23, .	0.1	0

#	Article	IF	CITATIONS
19	239â€fRole of eNOS genetic variants on ischaemic heart disease susceptibility and acute coronary syndrome presentation. European Heart Journal Supplements, 2021, 23, .	0.1	0
20	288â€fThe effects of cardiovascular diseases and treatment on clinical course of hospitalized COVID-19 patients. European Heart Journal Supplements, 2021, 23, .	0.1	0
21	282â€fFollow-up of hospitalized COVID-19 survivors: assessment of short- and long-term cardiovascular sequelae after SARS-CoV-2 infection. European Heart Journal Supplements, 2021, 23, .	0.1	0
22	Structural and myocardial dysfunction in heart failure beyond ejection fraction. Heart Failure Reviews, 2020, 25, 9-17.	3.9	32
23	Coronavirus disease 2019 in Rome: was it circulating before December?. Journal of Cardiovascular Medicine, 2020, 21, 835-836.	1.5	4
24	How to perform a cardio-thoracic magnetic resonance imaging in COVID-19: comprehensive assessment of heart, pulmonary arteries, and lung parenchyma. European Heart Journal Cardiovascular Imaging, 2020, 22, 728-731.	1.2	12
25	Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. International Journal of Molecular Sciences, 2020, 21, 8118.	4.1	148
26	Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels. International Journal of Molecular Sciences, 2020, 21, 3167.	4.1	72
27	Cardiovascular Magnetic Resonance and Sport Cardiology: a Growing Role in Clinical Dilemmas. Journal of Cardiovascular Translational Research, 2020, 13, 296-305.	2.4	20
28	2D/3D Echocardiographic features of patients with reverse remodeling after cardiac resynchronization therapy. Echocardiography, 2019, 36, 1475-1481.	0.9	3
29	Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist. Diagnostics, 2019, 9, 170.	2.6	36
30	Prevention of Cardiovascular Disease: Screening for Magnesium Deficiency. Cardiology Research and Practice, 2019, 2019, 1-10.	1.1	36
31	Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography. Cardiology Research and Practice, 2019, 2019, 1-7.	1.1	5
32	Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow. Journal of Diabetes Research, 2019, 2019, 1-16.	2.3	49
33	Triggers for Atrial Fibrillation: The Role of Anxiety. Cardiology Research and Practice, 2019, 2019, 1-5.	1.1	45
34	Giant right atrium and subvalvular pulmonary stenosis: A case report of an interesting combination. Echocardiography, 2019, 36, 992-995.	0.9	3
35	Mid-term repair durability after MitraClip implantation in patients with functional mitral regurgitation. Journal of Cardiovascular Medicine, 2019, 20, 701-708.	1.5	6
36	2D/3D echocardiographic determinants of left ventricular reverse remodelling after MitraClip implantation. European Heart Journal Cardiovascular Imaging, 2019, 20, 558-564.	1.2	22

3

#	Article	IF	CITATIONS
37	Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	2.8	145
38	Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. Circulation, 2017, 136, 126-137.	1.6	286
39	Left Ventricular Hypertrophy Revisited. Circulation, 2017, 136, 2519-2521.	1.6	37
40	Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis― Circulation, 2016, 133, e450-1.	1.6	4
41	Automatic Measurement of the MyocardialÂlnterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127
42	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 64.	3.3	19
43	Noncontrast myocardial $<$ i> $>$ T $<$ i> $<$ sub>1 $<$ sub> mapping using cardiovascular magnetic resonance for iron overload. Journal of Magnetic Resonance Imaging, 2015, 41, 1505-1511.	3.4	139
44	Cardiovascular magnetic resonance of a hiatus hernia causing positional cardiac compression. European Heart Journal Cardiovascular Imaging, 2015, 16, 818-818.	1.2	0
45	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2,2	310
46	Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. International Journal of Cardiology, 2015, 183, 143-148.	1.7	55
47	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
48	Extracellular volume quantification in isolated hypertension - changes at the detectable limits?. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 74.	3.3	79
49	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
50	Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 178-188.	2.9	199
51	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
52	T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. Current Cardiovascular Imaging Reports, 2014, 7, 9287.	0.6	37
53	Abnormal Cardiac Formation in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2014, 7, 241-248.	5.1	74
54	T1 Mapping for Myocardial Extracellular Volume Measurement by CMR. JACC: Cardiovascular Imaging, 2013, 6, 955-962.	5. 3	245

#	Article	IF	CITATIONS
55	Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circulation: Cardiovascular Imaging, 2013, 6, 392-398.	2.6	399
56	Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis. Circulation: Cardiovascular Imaging, 2013, 6, 34-39.	2.6	261
57	Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart, 2012, 98, 1436-1441.	2.9	276
58	Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 87.	3.3	207